FTAI vs REPL
FTAI: FTAI Aviation is a specialized aerospace platform that optimizes narrowbody aircraft engine life cycle management through its proprietary repair, exchange, and leasing business models. REPL: Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in combination therapy for melanoma patients who have failed checkpoint inhibitors.
Side-by-side fundamentals
| Metric | FTAI | REPL | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $221.23 | $12.86 | |
| Market cap as of 2026-08-08 | $22.7B | $1.1B | |
| P/E as of 2026-08-08 | 44.75 | n/a | |
| PEG as of 2026-08-08 | 0.72 | -0.40 | REPL lower |
| Net margin as of 2026-08-08 | +15.9% | n/a | |
| Gross margin as of 2026-08-08 | +39.2% | n/a | |
| Operating margin as of 2026-08-08 | +24.5% | n/a | |
| ROE as of 2026-08-08 | +139.6% | -128.6% | FTAI higher |
| ROA as of 2026-08-08 | +11.3% | -82.3% | FTAI higher |
| Debt / equity as of 2026-08-08 | 8.55 | 0.65 | REPL lower |
| Revenue growth (YoY) as of 2026-08-08 | +45.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +52.4% | n/a | |
| Dividend yield as of 2026-08-08 | +0.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 3 | n/a | |
| Beta as of 2026-08-08 | 1.52 | 0.88 | |
| 1-year return as of 2026-08-06 close | n/a | +133.8% |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.